ESMO PRECEPTORSHIP PROGRAMME
MOLECULAR CANCER BIOLOGY FOR PRACTISING ONCOLOGISTS
AND CANCER TREATMENT DE-ESCALATION
Multidisciplinary management, standards of care and future perspectives

Lugano, Switzerland
18-19 May 2022

CO-CHAIRS:  Michiel H. Strijbos, Belgium
Hendrik K. van Halteren, Netherlands

SPEAKERS:  Catherine Alix-Panabieres, France
Jaafar Bennouna, France
Birutė Brasiniene, Lithuania
Alberto J. Cunquero Tomás, Spain
Bram De Laere, Belgium
Piet Dirix, Belgium
Alice Indini, Italy
Gabor Liposits, Denmark
Benedetta Pellegrino, Italy
Lazar S. Popovic, Serbia
Radu A. Vidra, Romania

LEARNING OBJECTIVES

- Deliver an overview on novel molecular analyses techniques
- Illustrate the development of precision medicine in several tumour types
- Provide a state-of-the-art overview on evidence-based de-escalation strategies
- Explore the application to various tumour types

Wednesday, 18 May 2022

| 09:00-09:15 | 15’ | Welcome and Course Introduction  
Introduction Topic 1: Molecular Biology for Practising Oncologists | Michiel H. Strijbos, BE |
|---|---|---|---|
| 09:15-10:45 | 90’ | SESSION 1  
The use of biomarkers in clinical practice | Chair: Lazar S. Popovic, RS |
<p>| 30’ | Molecular analysis techniques for the practising oncologist | Bram De Laere, BE |
| 15’ | Discussion | Faculty |
| 30’ | Liquid biopsies: indications and limitations | Catherine Alix-Panabieres, FR |
| 15’ | Discussion | Faculty |
| 10:45-11:15 |  | Coffee break |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15-12:00</td>
<td>SESSION 2 Biomarkers-driven research</td>
<td>Alice Indini, IT</td>
</tr>
<tr>
<td>30’</td>
<td>Biomarkers-driven research</td>
<td>Lazar S. Popovic, RS</td>
</tr>
<tr>
<td>15’</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>12:00-14:30</td>
<td>SESSION 3 Precision Medicine in Colorectal cancer and in NSCLC</td>
<td>Gabor Liposits, DK</td>
</tr>
<tr>
<td>25’</td>
<td>State-of-the-art: Treatment decision based on biomarkers in Colorectal cancer</td>
<td>Hendrik K. van Halteren, NL</td>
</tr>
<tr>
<td>10’</td>
<td>Participant clinical case discussion (1x10’)</td>
<td>Faculty</td>
</tr>
<tr>
<td>10’</td>
<td>Discussion</td>
<td>Radu A. Vidra, RO</td>
</tr>
<tr>
<td>12:45-13:45</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>25’</td>
<td>State-of-the-art: Treatment decision based on biomarkers in NSCLC</td>
<td>Jaafar Bennouna, FR</td>
</tr>
<tr>
<td>10’</td>
<td>Participant clinical case discussion (1x10’)</td>
<td>Faculty</td>
</tr>
<tr>
<td>10’</td>
<td>Discussion</td>
<td>Michiel H. Strijbos, BE</td>
</tr>
<tr>
<td>14:30-15:30</td>
<td>SESSION 4 Melanoma and non skin cancers</td>
<td>Alberto J. Cunquero Tomas, ES</td>
</tr>
<tr>
<td>60’</td>
<td>State-of-the-art: Treatment decision based on biomarkers - Molecular biology for melanoma</td>
<td>Alice Indini, IT</td>
</tr>
<tr>
<td>25’</td>
<td>Participant clinical case discussion (1x10’)</td>
<td>Faculty</td>
</tr>
<tr>
<td>10’</td>
<td>Discussion</td>
<td>Birute Brasiumiene, LT</td>
</tr>
<tr>
<td>15’</td>
<td>Concluding remarks Topic 1</td>
<td>Alberto J. Cunquero Tomas, ES</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16:00-16:10</td>
<td>Introduction Topic 2: Cancer Treatment De-Escalation</td>
<td>Radu A. Vidra, RO</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:10-16:30</td>
<td>SESSION 5 Are we overtreating patients?</td>
<td>Gabor Liposits, DK</td>
</tr>
<tr>
<td>20’</td>
<td>Overview of the concept and rational for treatment de-escalation</td>
<td>Radu A. Vidra, RO</td>
</tr>
<tr>
<td>16:30-17:20</td>
<td>SESSION 6 Adjuvant colon and rectal cancer</td>
<td>Radu A. Vidra, RO</td>
</tr>
<tr>
<td>50’</td>
<td>Participant clinical case discussion (1x10’)</td>
<td>Faculty</td>
</tr>
<tr>
<td>30’</td>
<td>Improved cure with adjuvant treatment for how many? Present data on shorter duration of adjuvant colon treatment Better patient selection based on prognosis and biomarker MSI Definitive Chemoradiation and wait and see in cCR</td>
<td>Gabor Liposits, DK</td>
</tr>
<tr>
<td>10’</td>
<td>Discussion</td>
<td>Hendrik K. van Halteren, NL</td>
</tr>
</tbody>
</table>
### Thursday, 19 May 2022

**09:00-09:50 50’**  
**SESSION 8**  
Surgery & radiotherapy in breast cancer: conservative Breast surgery  
**Chair:** Birute Brasuiiene, LT  
- **10’** Participant clinical case discussion (1x10’)  
  Faculty  
- **30’** Standards of care & Future developments  
  TBC  
- **10’** Discussion  
  Birute Brasuiiene, LT  
  TBC  

**09:50-10:40 50’**  
**SESSION 9**  
Systemic therapy in breast cancer  
**Chair:** Benedetta Pellegrino, IT  
- **10’** Participant clinical case discussion (1x10’)  
  Faculty  
- **30’** De-escalation in Breast cancer  
  Lazar S. Popovic, RS  
- **10’** Discussion  
  Benedetta Pellegrino, IT  

**10:40-11:10**  
Coffee break  

**11:10-12:00 50’**  
**SESSION 10**  
Prostate cancer  
**Chair:** Michiel H. Strijbos, BE  
- **10’** Participant clinical case discussion (1x10’)  
  Faculty  
- **30’** Watch and Wait  
  Definitive Radiation therapy vs surgery  
  Piet Dirix, BE  
- **10’** Discussion  
  Michiel H. Strijbos, BE  
  Birute Brasuiiene, LT  
  Piet Dirix, BE  

**12:00-12:50 50’**  
**SESSION 11**  
Bladder cancer  
**Chair:** Hendrik K. van Halteren, NL  
- **10’** Participant clinical case discussion (1x10’)  
  Faculty  
- **30’** Chemoradiation to avoid cystectomy  
  Lazar S. Popovic, RS  
- **10’** Discussion  
  Hendrik K. van Halteren, NL  
  Lazar S. Popovic, RS  

**12:50-13:00 10’**  
**Conclusion Topic 2**  
Closing remarks  
**Chair:** Hendrik K. van Halteren, NL  

**13:00-14:00**  
Lunch  

**Note:** Each 10-minute slot for clinical case discussion includes 5’ case presentation and 5’ Q&A / panel discussion